Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Regulus Therapeutics Inc. (NASDAQ: RGLS) resulting from allegations that Regulus Therapeutics may have issued materially misleading business information to the investing public.

On June 27, 2016, Regulus Therapeutics announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed the Regulus Therapeutics’ investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported. On this news, shares of Regulus Therapeutics sharply during intraday trading on June 28, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Regulus Therapeutics investors. If you purchased shares of Regulus Therapeutics on or before June 27, 2016, please visit the website at http://rosenlegal.com/cases-916.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.